Avoid Euphoria and Undue Pessimism Alike<br />By Rev Shark<br />RealMoney.com Contributor<br />7/21/2009 9:11 AM EDT <br /><br />It is a mistake to look too far ahead. Only one link in the chain of destiny can be handled at a time. <br />-- Winston Churchill<br /><br />The Nasdaq has been up nine days in a row for the first time in about 10 years. With a highly anticipated positive earnings report from Apple (AAPL) tonight and some good earnings from Caterpillar (CAT) , Freeport-McMoRan (FCX) , Coke (KO) and Texas Instruments (TXN) this morning, the quest for a 10th day of gains is off to a good start. <br /><br />Earnings reports continue to show good bottom-line results relative to expectations due primarily to massive cost-cutting, but revenue growth has been anemic at best. The market doesn't much care right now, and as long as the bottom-line number beats analysts' expectations we are seeing positive results. Even stocks that have run up quite a bit the past week such as CAT are jumping on their numbers. One exception is TXN, which had a solid report but is seeing a "sell the news" reaction after running straight up since the Intel (INTC) report last week. <br /><br />The market has had a remarkable move over the past week, with an almost parabolic rise. A lot of folks like those on CNBC's "Fast Money" are giddy with delight, but for market players looking to make new buys, this market presents quite a dilemma. Obviously we have very strong momentum, as we have been going straight up, but that produces extended and overbought charts that don't invite good entries. In addition, with more major earnings reports, the potential for a "sell the news" reaction is increased. It is going to be particularly interesting to see how AAPL reacts tonight. Expectations are extremely high and the stock has moved up from about $136 to $153 over the past week as everyone is looking for blowout numbers. <br /><br />So do we take our idle cash and dive into this market that has gone straight up for nine days in a row now? Maybe if we can find stocks that aren't too extended already. There are some, but they are tough to find and if they have been lagging the market, you have to wonder if there is a reason for it. <br /><br />Even if you are unwilling to pay up for some of these stocks that have made big moves, that doesn't mean you should be unduly bearish or aggressively shorting. One of the keys to success in the market is to not fight the prevailing trend. Markets that are trending strongly don't quickly or easily reverse. There is always a big group of folks who have been left behind who are anxious to jump in on slight pullbacks. That underlying support will only go away after the market has struggled for a bit and stops making major gains. <br /><br />The important thing now is to not get sucked into the euphoria after the market has already made its move -- don't throw caution to the wind. If you are going to make some buys, then stay disciplined and don't just grab something because you are frustrated with not being more heavily invested over the past week. <br /><br />With AAPL earnings tonight and Ben Bernanke testifying before Congress today, the market is likely to hold steady. With the number of extended stocks out there, though, new buys are going to be very difficult. <br />--------------------------------------------------<br />Ülespoole avanevad:<br /><br />In reaction to strong earnings/guidance: JDAS +21.1%, LAB +14.9% (light volume), PKG +14.8% (upgraded to Buy at Deutsche), USPH +13.3%, MAIL +12.7%, CAT +10.1%, JEF +8.4%, LM +5.5%, MICC +5.2%, UNH +4.9%, DD +4.0%, MRK +3.3%, BSX +2.9%, FCX +2.8%, AMTD +2.7%, ELN +2.5%, MDRX +2.0%, DGX +2.0%, BLK +1.7%... Select solar names ticking higher: JASO +6.4%, YGE +5.7%, SOL +5.6%, STP +5.3%, TSL +3.1%, FSLR +2.8%... Select construction/ag related names showing strength boosted by CAT results: MTW +6.1%, DE +4.4%, JOYG +4.3%, TEX +2.8%... Select casino related names trading higher: LVS +5.0% (upgraded to Outperform from Market Perform at BMO Capital), WYNN +3.9%, ACAS +2.8%... Other news: CGEN +13.5% (announces 'positive' therapeutic effects of novel peptide in animal model of retinopathy), LXRX +12.9% (light volume; drug candidate LX1032 for carcinoid syndrome receives orphan drug designation from EMEA), PLX +10.5% (still checking), HNT +9.8% (UnitedHealthcare to acquire Health Net's Northeast licenses and rights to renew membership), CIT +8.0% (announces $3 bln credit facility and initiates recapitalization plan), ALKS +7.0% (Exenatide once weekly provided superior glucose control compared to Lantus in head-to-head DURATION-3 study), INCY +5.8% (reaches agreement with FDA on a Special Protocol Assessment for INCB18424 in myelofibrosis), RBS +4.0% (still checking), SPPI +3.9% (says FDA designates Fast Track status for Apaziquone for bladder cancer), MON +3.1% (Monsanto, Dow AgroSciences complete U.S. and Canadian Regulatory Authorizations for SmartStax corn; plans set to launch seed platform on 3-4 mln-plus acres), AMLN +1.1% (Exenatide once weekly provided superior glucose control compared to Lantus in head-to-head DURATION-3 study)... Analyst comments: IP +6.2% (upgraded to Buy at Deutsche), USB +1.1% (initiated with an Outperform at Credit Suisse).<br /><br />Allapoole avanevad:<br /><br />In reaction to disappointing earnings/guidance: IDIX -10.0%, LXK -9.4%, RF -8.7%, ZION -6.7% (also downgraded to Sell at Citigroup), FWRD -5.6% (light volume), WERN -4.1%, STT -3.9%, EW -2.7%, ICUI -2.4%, BTU -2.4%, TXN -1.9%, UTX -1.7%... Other news: CVBF -8.0% (commences an offering of ~$115 mln of its common stock in an underwritten public offering), CGA -6.4% (prices 3.5 mln share common stock offering at $7.15/share), STSA -6.3% (announces filing of universal shelf registration), CEDC -1.7% (prices 8.35 mln common share offering at $24.00/share)... Analyst comments: CTXS -3.0% (downgraded to Underperform at BofA/Merrill), TK -1.9% (downgraded to Underweight at JPMorgan).